Fillers & Injections
Original price was: $290.00.$235.00Current price is: $235.00.
| Product Brand: | JUVEDERM |
| Application: | Professional |
| Composition: | Hyaluronic acid gel + Lidocaine + Phosphate buffer |
| Target Areas: | Lip volume, facial contour, and jugal wrinkles |
JUVÉDERM VOLIFT RETOUCH LIDOCAINE 2×0.55 ml is a hyaluronic acid based dermal filler intended for wrinkle correction, touch-up procedures, and minor face refinement. It is part of the JUVÉDERM® line of injectable cosmetics designed for skin rejuvenation and face sculpting.
JUVÉDERM® VOLIFT RETOUCH LIDOCAINE 2×0.55 ml is a very precise injectable filler that uses VYCROSS™ technology to enhance and refresh facial contouring results.
Allergan Aesthetics (an AbbVie business) created this premium filler, which blends hyaluronic acid (17.5 mg/ml) and lidocaine (0.3%) to ensure both outcomes that look natural and increased patient comfort.
It is suitable for touch-ups after first JUVÉDERM® VOLIFT treatments, enabling for minor volume corrections and particular contouring without overcorrection.
JUVÉDERM VOLIFT RETOUCH Filler (2×0.55 ml) is a popular option for face rejuvenation because of its many comfort and aesthetic benefits. The main advantages are as follows:
This product is a medical device that can only be used by a qualified practitioner who has been given permission to inject fillers made of hyaluronic acid. Less than fifteen minutes may pass during the injection.
Two weeks following the original treatment, touch-ups are treated with Juvederm VOLIFT RETOUCH.
Injection method: A tiny needle is inserted into the deep dermis to administer the injection.
A particularly comfortable treatment is ensured for the patient by the fluidity of the gel and the presence of lidocaine (3D Matrix Technology).
Effectiveness duration: The injection’s effects are apparent right away. The patient’s age and the amount administered determine how long they last. Up to 15 months may pass while using the Juvéderm VOLIFT RETOUCH line.
Reviews
There are no reviews yet.